BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 21653692)

  • 1. Enhanced metastasis suppression by targeting TRAIL receptor 2 in a murine model of triple-negative breast cancer.
    Malin D; Chen F; Schiller C; Koblinski J; Cryns VL
    Clin Cancer Res; 2011 Aug; 17(15):5005-15. PubMed ID: 21653692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
    Strekalova E; Malin D; Good DM; Cryns VL
    Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib.
    Luster TA; Carrell JA; McCormick K; Sun D; Humphreys R
    Mol Cancer Ther; 2009 Feb; 8(2):292-302. PubMed ID: 19174554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
    Belyanskaya LL; Marti TM; Hopkins-Donaldson S; Kurtz S; Felley-Bosco E; Stahel RA
    Mol Cancer; 2007 Oct; 6():66. PubMed ID: 17953743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression.
    Wu XX; Jin XH; Zeng Y; El Hamed AM; Kakehi Y
    Cancer Sci; 2007 Dec; 98(12):1969-76. PubMed ID: 17922852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors.
    Stadel D; Mohr A; Ref C; MacFarlane M; Zhou S; Humphreys R; Bachem M; Cohen G; Möller P; Zwacka RM; Debatin KM; Fulda S
    Clin Cancer Res; 2010 Dec; 16(23):5734-49. PubMed ID: 20940278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
    Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
    Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
    Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
    Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
    Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
    J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
    Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
    Zhang L; Zhang X; Barrisford GW; Olumi AF
    Cancer Lett; 2007 Jun; 251(1):146-57. PubMed ID: 17184908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels.
    Nawrocki ST; Carew JS; Douglas L; Cleveland JL; Humphreys R; Houghton JA
    Cancer Res; 2007 Jul; 67(14):6987-94. PubMed ID: 17638911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
    Strekalova E; Malin D; Rajanala H; Cryns VL
    Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype.
    Rahman M; Davis SR; Pumphrey JG; Bao J; Nau MM; Meltzer PS; Lipkowitz S
    Breast Cancer Res Treat; 2009 Jan; 113(2):217-30. PubMed ID: 18266105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Surget S; Chiron D; Gomez-Bougie P; Descamps G; Ménoret E; Bataille R; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
    Cancer Res; 2012 Sep; 72(17):4562-73. PubMed ID: 22738917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
    Wu XX; Kakehi Y
    Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
    Natoni A; MacFarlane M; Inoue S; Walewska R; Majid A; Knee D; Stover DR; Dyer MJ; Cohen GM
    Br J Haematol; 2007 Nov; 139(4):568-77. PubMed ID: 17922877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
    Ganten TM; Sykora J; Koschny R; Batke E; Aulmann S; Mansmann U; Stremmel W; Sinn HP; Walczak H
    J Mol Med (Berl); 2009 Oct; 87(10):995-1007. PubMed ID: 19680616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma.
    Engesæter B; Engebraaten O; Flørenes VA; Mælandsmo GM
    PLoS One; 2012; 7(9):e45492. PubMed ID: 23029050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.